• Product name

  • Description

    Rabbit polyclonal to IRF1
  • Host species

  • Tested applications

    Suitable for: WB, IHC-Pmore details
  • Species reactivity

    Reacts with: Mouse, Rat, Human
    Predicted to work with: Dog, Pig, Monkey
  • Immunogen

    Synthetic peptide within Human IRF1 (internal sequence) conjugated to keyhole limpet haemocyanin. The exact sequence is proprietary.
    Database link: P10914

  • Positive control

    • WB: HEK-293T, RAW 264.7 and H9c2 whole cell lysate. IHC-P: Human small intestine gtissue.



Our Abpromise guarantee covers the use of ab230652 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Predicted molecular weight: 37 kDa.
IHC-P 1/100.


  • Function

    Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)) and activates those genes. Acts as a tumor suppressor.
  • Involvement in disease

    Defects in IRF1 are a cause of gastric cancer (GASC) [MIM:613659]; also called gastric cancer intestinal or stomach cancer. Gastric cancer is a malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.
  • Sequence similarities

    Belongs to the IRF family.
    Contains 1 IRF tryptophan pentad repeat DNA-binding domain.
  • Post-translational

    Sumoylation represses the transcriptional activity and displays enhanced resistance to protein degradation. Inactivates the tumor suppressor activity. Elevated levels in tumor cells. Major site is Lys-275. Sumoylation is enhanced by PIAS3 (By similarity). Desumoylated by SENP1 in tumor cells and appears to compete with ubiquitination on C-terminal sites.
    Ubiquitinated. Appears to compete with sumoylation on C-terminal sites.
  • Cellular localization

  • Information by UniProt
  • Database links

  • Alternative names

    • Interferon regulatory factor 1 antibody
    • Interferon regulatory factor 1 isoform +I9 antibody
    • Interferon regulatory factor 1 isoform d78 antibody
    • Interferon regulatory factor 1 isoform delta4 antibody
    • Interferon regulatory factor 1 isoform delta7 antibody
    • IRF 1 antibody
    • IRF-1 antibody
    • IRF1 antibody
    • IRF1_HUMAN antibody
    • MAR antibody
    • MAR1 antibody
    see all


  • Formalin-fixed, paraffin-embedded human small intestine tissue stained for IRF1 using ab230652 at 1/100 dilution in immunohistochemical analysis.

  • All lanes : Anti-IRF1 antibody (ab230652) at 1/500 dilution

    Lane 1 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
    Lane 2 : RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate
    Lane 3 : H9c2 (rat heart myoblast cell line) whole cell lysate

    Predicted band size: 37 kDa


ab230652 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab230652.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up